Moderna’s mRNA-based flu vaccine reveals promise in early-stage research

A vial and a syringe are seen in entrance of a displayed Moderna emblem, on this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Picture

Moderna Inc’s messenger RNA-based experimental seasonal flu vaccine has produced strong antibodies in opposition to all 4 strains of the influenza virus in an early stage research, the vaccine maker mentioned on Friday.

The early-stage research is ongoing and a mid-stage research testing of the vaccine, mRNA-1010, is now totally enrolled, the corporate mentioned.

This information, although restricted, places Moderna forward of different drugmakers, together with rival Pfizer Inc, which are additionally testing their flu vaccine primarily based on messenger RNA.

Moderna additionally mentioned it was creating a pan-respiratory annual booster vaccine, which might goal a number of viruses together with COVID-19, flu and Respiratory syncytial virus.

The brand new vaccine, mRNA-1345, has demonstrated constructive early-stage outcomes, it mentioned.

“Even earlier than the COVID-19 pandemic, roughly three million individuals died every year on account of respiratory infections … our objective is to restrict this struggling with an annual pan-respiratory single dose booster vaccine,” Chief Government Officer Stéphane Bancel mentioned. 

See also  Consuming meat might improve danger of fatty liver illness